SRGN and breast carcinoma: In addition to lung cancer, SRGN has also been reported to promote aggressive phenotypes in breast cancer cells by inducing epithelial-mesenchymal transition, and up-regulating the production of proteolytic activity and proinflammatory cytokines, including IL-8 [55].